Evidence map›Paper›PMID 41560588›Full record

ArticleDiabetes, obesity & metabolism2026

BALLAST study: A multicentre, open-label, randomized-controlled, 52-week clinical trial of the efficacy and safety of luseogliflozin in older Japanese adults with type 2 diabetes receiving leucine-enriched amino acid supplementation and physical exercise programme.

Yoshihiro Takahashi, Makoto Hayashi, Takehiro Kato, Yukio Horikawa, Shin Tsunekawa, Hitoshi Kuwata, Yutaka Seino, Ryota Ogata, Kenta Murotani, Daisuke Yabe and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoshihiro TakahashiDepartment of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0002-4841-9914
Makoto HayashiDepartment of Diabetes and Endocrinology/Diabetes Center, Matsunami General Hospital, Gifu, Japan.ORCID https://orcid.org/0009-0002-1403-8205
Takehiro KatoDepartment of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0003-3236-2463
Yukio HorikawaDepartment of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0001-7268-6871
Shin TsunekawaDepartment of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0002-9890-5777
Hitoshi KuwataYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0009-0000-5498-3282
Yutaka SeinoYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0000-0002-1099-7989
Ryota OgataDepartment of Biostatistics, Graduate School of Medicine, Kurume University, Kurume, Japan.ORCID https://orcid.org/0009-0006-9415-3412
Kenta MurotaniSchool of Medical Technology, Kurume University, Kurume, Japan.ORCID https://orcid.org/0000-0003-0623-9365
Daisuke YabeDepartment of Diabetes, Endocrinology and Metabolism/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0002-5334-7687
BALLAST Study Group

Funding

Taisho Pharmaceutical, Co., Ltd.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

older adultrandomised clinical trialsarcopeniaSGLT2 inhibitortype 2 diabetes

Identifiers

PMID41560588
PMCPMC12992172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.